Bazdaca ML 200mg Injection

Bazdaca ML 200mg Injection is an antineoplastic drug belonging to the class of alkylating agents, containing the active ingredient Dacarbazine. It is used to prevent and treat metastatic malignant melanoma and Hodgkin's disease. It is often combined with cisplatin, a cytotoxic agent, for treatment of certain cancers including Hodgkin's lymphoma, and with temozolomide for treatment of melanoma. There may be an increased risk of non-melanoma skin cancer with use of this medicine.

This drug is contraindicated in pregnant women. Women of childbearing potential should use effective contraception during and for at least 6 months after treatment. It is not known whether Bazdaca ML 200mg Injection is excreted in human milk; breastfeeding should be avoided during treatment. Use with caution in patients with pre-existing liver or kidney dysfunction.

Do not receive a live vaccine while taking Bazdaca ML 200mg Injection, as it may weaken the immune system and increase risk of serious infection. Bazdaca ML 200mg Injection may cause pain along the vein. Inform your nurse immediately if you experience pain so the infusion site can be checked. The infusion may be administered more slowly or flushed with additional fluids to reduce discomfort.

Treatment should not be started if white blood cell counts have fallen below determined levels. Your doctor will establish these values at regular intervals. This medicine should not be used if you are allergic to Dacarbazine. Blood tests will be performed before each administration to confirm adequate blood cell counts. It is usually administered once every three to four weeks.

Inform your physician about all medications you have been taking recently, including herbal medicines and supplements, before taking Bazdaca ML 200mg Injection.

Dacarbazine is used in the treatment of the following: Metastatic malignant melanoma Hodgkin’s disease

It is a type of alkylating agent that works mainly through the process of alkylation. It enters the cancer cells after getting activated by the liver and inhibits DNA synthesis. This process disrupts the normal cell cycle and DNA function, leading to arrest in cancer cell growth and multiplication.

The medicine will be administered to you by a healthcare professional in a hospital setting. This injection will be given intravenously into a vein in your arm or hand. Do not self-administer this medicine. The specific dose and schedule of administration depend on the type and stage of cancer being treated. Bazdaca ML 200mg Injection is usually given about 30 minutes before you receive your anti-cancer medicine (chemotherapy). During the infusion, you will be monitored for any side effects or reactions to the medication. It is important to get the dose at the scheduled time. If you missed the schedule, contact your doctor and reschedule the dose.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious side effects of Bazdaca ML 200mg Injection are: Sore throat or high temperature indicating infection Unusual bleeding or bruising Severe vomiting or diarrhoea Extreme tiredness Severe allergic reaction, characterised by swelling of hands, feet, ankles, face, lips, mouth or throat; rashes or giddiness. Headache, vision problems, fits, confusion, lethargy or numbness of face Severe liver problems Common side effects of Bazdaca ML 200mg Injection are: Low levels of RBC, WBC and platelets in blood. Loss of appetite Nausea, vomiting Hair loss Skin reactions

Bazdaca ML 200mg Injection can cause harm to a developing fetus or nursing baby, so it is important to discuss contraception options and the need to avoid breastfeeding during treatment. This drug causes fatigue, so encourage the patient to take enough rest and self-care during treatment. Bazdaca ML 200mg Injection increases the risk of bleeding and bruising, so it is important to be careful when using sharp objects or participating in activities that may result in injury.